Keytruda Demonstrates Significant Improvement for Some Patients with Melanoma
Keytruda, an immunotherapy agent, demonstrated significant improvement in both distant metastasis-free survival and recurrence-free survival compared to placebo.
Novel Drug Combo Induces Encouraging Results in Patients With Heavily Pretreated Breast Cancer
The use of Faslodex plus the investigational drug samuraciclib was considered safe in individuals with heavily pretreated hormone receptor-positive breast cancer.